Form 4 for IMNM Immunome Inc.

Accepted 2023-10-04 00:00:00 ET · period of report 2023-10-02 · accession 0001209191-23-052048 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-10-04	2023-10-02	IMNM	PRENDERGAST FRANKLYN G	Dir	A - Grant	$0.00	+60.8K	60.8K	New	$0
D	2023-10-04	2023-10-02	IMNM	PRENDERGAST FRANKLYN G	Dir	A - Grant	$1.35	+137.7K	137.7K	New	+$185.9K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-10-02	A	A	60,840	$0.00	60,840	D	—	—	(F1) In connection with the Closing (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by an among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.), Dr. Prendergast exchanged (i) his shares of common stock of Morphimmune for shares of the Issuer and (ii) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer.
2	Derivative	Stock Option (Right to Buy)	2023-10-02	A	A	137,725	$1.35	137,725	D	$1.35 · — to 2032-09-26	137,725 Common Stock	(F1) In connection with the Closing (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by an among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.), Dr. Prendergast exchanged (i) his shares of common stock of Morphimmune for shares of the Issuer and (ii) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer. (F2) In connection with the Closing (as defined in the Merger Agreement), all the shares underlying the option became fully vested and exercisable.